Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis

The nucleotide analogue azacitidine (AZA) is currently the best treatment option for patients with high-risk myelodysplastic syndromes (MDS). However, only half of treated patients respond and of these almost all eventually relapse. New treatment options are urgently needed to improve the clinical m...

Descripción completa

Detalles Bibliográficos
Autores principales: Diesch, Jeannine, Le Pannérer, Marguerite-Marie, Winkler, René, Casquero, Raquel, Muhar, Matthias, van der Garde, Mark, Maher, Michael, Herráez, Carolina Martínez, Bech-Serra, Joan J., Fellner, Michaela, Rathert, Philipp, Brooks, Nigel, Zamora, Lurdes, Gentilella, Antonio, de la Torre, Carolina, Zuber, Johannes, Götze, Katharina S., Buschbeck, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523560/
https://www.ncbi.nlm.nih.gov/pubmed/34663789
http://dx.doi.org/10.1038/s41467-021-26258-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523560/
https://www.ncbi.nlm.nih.gov/pubmed/34663789
http://dx.doi.org/10.1038/s41467-021-26258-z

Ejemplares similares